FOR IMMEDIATE RELEASE:

Quincy Bioscience Names Dr. James Moyer as Scientific Advisor

RICHFIELD, Wisconsin (September 22, 2004)

Quincy Bioscience, a developer of therapeutic products for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, announced the appointment of Dr. James R. Moyer, Jr. as the company's Scientific Advisor.

Dr. Moyer is currently an Assistant Professor in the department of Psychology (Neuroscience) with an adjunct position in the department of Biological Sciences at the University of Wisconsin at Milwaukee. Dr. Moyer received his Ph.D. in Cell Biology from Northwestern University in 1992. He served in postdoctoral positions at both Northwestern University and Yale University before his current position at UW-M. Over the years, Dr. Moyer's research has focused on investigating neurophysiological, cellular, and behavioral changes that occur during both associative learning and aging.

"I feel that the addition of Dr. Moyer strengthens the technology foundation upon which Quincy Bioscience is being built. I think the next several months are going to be particularly exciting," said Mark Underwood, Vice President of Product Development at Quincy. "We have been looking for someone with the right mixture of experience in the field that we are exploring and Dr. Moyer is a perfect fit."

Mike Beaman, Quincy Bioscience President and CEO said, "We are truly pleased that Dr. Moyer has affiliated with Quincy Bioscience and we look forward to his contributions in the laboratory to help answer some critical research questions. Dr. Moyer is the right person to help us explore the physiological and behavioral aspects of our new therapeutic compounds."

Quincy Bioscience develops therapeutics to address the imbalance of calcium ions that is commonly thought to be related to the neuronal degeneration seen in such diseases. The company has identified a unique molecule (aequorin) that will form the basis of its products aimed at fighting the diseases of aging. Many different conditions are related to the disruption of calcium homeostasis, and aequorin is being investigated to see how it may help restore the balance of that critical ion in the human body. Aequorin is non-toxic and has been shown to perform well in cells. The company has already applied for patent protection.

Profile for Dr. James R. Moyer, Jr.

For more information, contact Mark Underwood at munderwood@quincybioscience.com or toll-free at 877-677-8652.